Plasma β-synuclein, GFAP, and neurofilaments in patients with malignant gliomas undergoing surgical and adjuvant therapy

Ann Clin Transl Neurol. 2023 Oct;10(10):1924-1930. doi: 10.1002/acn3.51878. Epub 2023 Aug 23.

Abstract

We analyzed the longitudinal concentrations and prognostic roles of plasma β-synuclein (β-syn), glial fibrillary acidic protein (GFAP), and neurofilament proteins (NfL and NfH) in 33 patients with malignant gliomas, who underwent surgical and adjuvant therapy. GFAP and NfL levels were increased in patients with glioblastoma compared to cases with other tumors. β-syn, NfL and NfH increased after surgery, whereas GFAP decreased at long-term follow-up. β-syn and neurofilament concentrations were influenced by surgery and/or radiotherapy regimens. GFAP and neurofilament levels were significantly associated with survival. Plasma neuronal and astrocytic biomarkers are differentially altered in malignant glioma types and displayed distinct trajectories after surgical and adjuvant therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Glial Fibrillary Acidic Protein
  • Glioma* / surgery
  • Humans
  • Intermediate Filaments* / metabolism
  • beta-Synuclein

Substances

  • Glial Fibrillary Acidic Protein
  • beta-Synuclein
  • Biomarkers

Grants and funding

This work was funded by Boehringer Ingelheim Ulm University BioCenter grant D.5009; EU Joint Programme‐Neurodegenerative Diseases (JPND) network ; EU Moodmarker program grant 01EW2008; Foundation of the State Baden‐Württemberg grant D.3830; Genfi‐Prox grant 01ED2008A; German Federal Ministry of Education and Research grant FTLDc 01GI1007A; German Research Foundation/DFG grant SFB1279; Medical Faculty of the Martin‐Luther‐University Halle‐Wittenberg grant CS22/06; Roux program of the Martin Luther University Halle‐Wittenberg; Thierry Latran foundation grant D.2468.